Scemblix Approved to Treat Chronic Myeloid Leukemia
October 29, 2021Purified Cortrophin Gel Approved
November 1, 2021October 29, 2021 – Comirnaty® (COVID-19 vaccine, mRNA – Pfizer/BioNTech) has received emergency use authorization (EUA) to prevent COVID-19 in children 5-11 years of age.
- Recommended dosing for the primary vaccination series in children 5-11 years old is two 0.2mL intramuscular injections given three weeks apart. This is lower than the 0.3mL per injection dosing recommended for the primary dosing series in individuals ages 12 years and up.
- An EUA does not constitute full FDA approval. However, the FDA has determined, based on the totality of available scientific evidence, that the known and potential benefits of the vaccine in children at least five years old outweigh the known and potential risks.